This study included 259 LRRK2-PD and 318 LRRK2-asymptomatic participants; regular NSAID use resulted in reduced risk for PD in the overall cohort (OR: 0.34), including LRRK2 p.G2019S, p.R1441C/G, p.I2020T, p.G2385R, and p.R1628P variants [134]. This evidence concerns the gene LRRK2 and Parkinson disease.